A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
11/2011
11/16/2011	CN101845051B Nitrogen-containing heterocyclic thienopyridine compounds and preparation method and application thereof
11/16/2011	CN101838317B Mimic short peptide 11B of endothelial cell growth factor VEGF antigen epitope and application thereof
11/16/2011	CN101838310B Basic fibroblast growth factor epitope simulative peptide T3 and application thereof
11/16/2011	CN101812452B Application of small interfering RNA (Ribonucleic Acid) of RALA (v-ral simian leukemia viral oncogene homolog A) gene in preparing medicaments for resisting leukemia
11/16/2011	CN101792401B Biphenyl compound with anti-tumor activity and preparation method thereof
11/16/2011	CN101785777B Application of bufotalin std. in preparing medicament for treating lung tumors
11/16/2011	CN101780074B Anti-lung cancer pharmaceutical composition
11/16/2011	CN101735236B Dimer citrinin compounds and preparation and use thereof
11/16/2011	CN101712700B Alkyl galactoside receptor, preparation method and application thereof
11/16/2011	CN101708308B Anti-tumor medicinal composition without stimulation to gastrointestinal mucosae
11/16/2011	CN101704813B 1'-thio-indigo red compound as well as application and preparation method thereof
11/16/2011	CN101693705B Phenol compound as well as preparation method and applications thereof
11/16/2011	CN101684100B Preparation method of dexrazoxane and pharmaceutical salts thereof
11/16/2011	CN101676401B Scorpion extract
11/16/2011	CN101676301B Antibody for inhibiting growth of colorectal carcinoma and its use in preparation of medicament and kit
11/16/2011	CN101665544B Chitosan grafting compound of cinnamic acid derivatives and application
11/16/2011	CN101654482B High specific anti-tumor monoclonal antibody
11/16/2011	CN101649312B Human plasminogen K5 modified by RGD and preparation method and application thereof
11/16/2011	CN101628931B Antitumor antibiotics, pharmaceutically acceptable salts thereof, preparation method thereof and use thereof
11/16/2011	CN101612126B Preparation of immunoliposome of CD19 monoclonal antibody and application
11/16/2011	CN101580755B Process for continuously extracting cordyceps militaris essential oil, cordycepin, cordycepic acid and cordyceps militaris polysaccharide from cordyceps militaris
11/16/2011	CN101522651B Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
11/16/2011	CN101511372B Anti-cancer therapy comprising an h2-blocker, at least one antiinflammatory agent and a cytotoxic agent
11/16/2011	CN101492539B Dichloro-platinum aspartate
11/16/2011	CN101429234B Vaccine based on simulating human blood vessel endothelial cell growth factor VEGF epitope and preparation method thereof
11/16/2011	CN101407812B Heterologous expression and purification method for human RANTES protein having chemotaxis
11/16/2011	CN101405014B Water having anticancer action and method for producing the same
11/16/2011	CN101395168B Galactose derivative,Drug carrier and medicinal composition
11/16/2011	CN101357144B Selaginella uncinata extraction, its preparation method and application
11/16/2011	CN101351477B Anti-CD19 antibodies with reduced immunogenicity
11/16/2011	CN101156914B Method for extracting triterpenic acid from Chinese date dregs
11/16/2011	CN101137364B Compositions comprising an epothilone and production methods
11/16/2011	CN101068826B Potent LNA oligonucleotides for the inhibition of HIF-1A expression
11/16/2011	CN101062041B Novel medical function of cucurbitacin
11/16/2011	CN101062040B Stable type cucurbitacin liquid formula and the agent thereof
11/15/2011	US8058445 Substituted pyridinecarboxamides for the treatment of cancer
11/15/2011	US8058430 Biologically active aphrocallistin compounds
11/15/2011	US8058426 Phosphorus-containing compounds and uses thereof
11/15/2011	US8058400 Composition and method for modulating dendritic cell-t cell interaction
11/15/2011	US8058399 Multispecific reagent for selectively stimulating cell surface receptors
11/15/2011	US8058344 Glycodendrimers having biological activity
11/15/2011	US8058314 Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
11/15/2011	US8058289 Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors
11/15/2011	US8058283 7H-pyrido[3,4-D]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors
11/15/2011	US8058282 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy
11/15/2011	US8058280 Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof
11/15/2011	US8058273 Histone deacetylases inhibitors
11/15/2011	US8058249 Immunostimulatory nucleic acid molecules
11/15/2011	US8058243 Method for treating a brain cancer with ifenprodil
11/15/2011	US8058045 Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use
11/15/2011	US8058025 Methods for determining efficacy of chemotherapeutic agents
11/15/2011	US8057825 Krill extracts for treatment of cardiovascular diseases
11/15/2011	US8057803 Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
11/15/2011	US8057799 ErbB interface peptidomimetics and methods of use thereof
11/15/2011	US8057791 Human antibodies specific to KDR and uses thereof
11/15/2011	CA2632286C Use of (r)-3-[1-(2,6-dichloro-3-fluror-phenyl)-ethoxyl]-5-(1-piperidin-4-yl-1h-pyrazol-4-yl)-pyridin-2-ylamine for treatment of cancer
11/15/2011	CA2632149C Pyrimidine derivatives for the treatment of abnormal cell growth
11/15/2011	CA2598690C Small molecule inhibitors of mdm2 and uses thereof
11/15/2011	CA2554709C Crystalline polymorphs of a cxc-chemokine receptor ligand
11/15/2011	CA2532193C 7-polyaminoalkyl(oxy)iminomethylcamptothecins bearing protective groups
11/15/2011	CA2505489C Pyrrolobenzodiazepines
11/15/2011	CA2489461C Tumour-inhibiting platinum (ii) oxalate complexes
11/15/2011	CA2488611C Compounds for modulating the activity of exchange proteins directly activated by camp (epacs)
11/15/2011	CA2479126C Combination treatments for chemokine-mediated diseases
11/15/2011	CA2476166C Anti-cd20 antibodies and fusion proteins thereof and methods of use
11/15/2011	CA2473175C The synthesis of naturally occurring ecteinascidins and related compounds
11/15/2011	CA2461989C Method for treating multiple myeloma
11/15/2011	CA2450473C Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571
11/15/2011	CA2435067C Malonyl-coa decarboxylase inhibitors useful as metabolic modulators
11/15/2011	CA2429979C Treatment of statin side effects
11/15/2011	CA2410387C Polymerizable compositions and methods of use
11/15/2011	CA2405715C Methods for selective targeting
11/15/2011	CA2385736C Mediators of hedgehog signaling pathways, compositions and uses related thereto
11/15/2011	CA2170641C Senescent cell-derived inhibitors of dna synthesis
11/10/2011	WO2011140527A2 Methods and compositions for inhibition of the transitional endoplasmic reticulum atpase
11/10/2011	WO2011140519A2 In vivo gelling pharmaceutical pre-formulation
11/10/2011	WO2011140517A2 Methods for treating diseases of the lung
11/10/2011	WO2011140488A1 Pyridone and aza-pyridone compounds and methods of use
11/10/2011	WO2011140334A2 Compounds, methods of making or identifying compounds, and uses thereof
11/10/2011	WO2011140295A2 Modulators of notch receptor signaling and methods of use thereof
11/10/2011	WO2011140267A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
11/10/2011	WO2011140255A1 Dendritic cell immunoreceptors (dcir)-mediated crosspriming of human cd8+ t cells
11/10/2011	WO2011140249A2 Antibodies that bind csf1r
11/10/2011	WO2011140190A1 Tetrazolones as inhibitors of fatty acid synthase
11/10/2011	WO2011140135A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
11/10/2011	WO2011140132A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
11/10/2011	WO2011139985A1 Compositions and methods for the diagnosis and treatment of tumor
11/10/2011	WO2011139951A1 Modulators of fatty acid amide hydrolase
11/10/2011	WO2011139907A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
11/10/2011	WO2011139891A1 Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites
11/10/2011	WO2011139868A2 Method for treating esophageal cancer
11/10/2011	WO2011139867A2 Method of treating brain cancer
11/10/2011	WO2011139843A2 Multi-sirna compositions for reducing gene expression
11/10/2011	WO2011139842A2 Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof
11/10/2011	WO2011139801A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl trna synthetases
11/10/2011	WO2011139799A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
11/10/2011	WO2011139791A2 Bisphosphonamidate prodrugs and uses thereof
11/10/2011	WO2011139769A2 Immunogenic compositions and methods for treating neoplasia
11/10/2011	WO2011139738A2 Therapies using zanolimumab to enhance the immune response
11/10/2011	WO2011139714A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase

1 ... 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 ... 2211